{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"300"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"Maximum tolerated dose for the recommended Phase 2 dose (RP2D) of LY3009120 that might be safely administered to participants with advanced and/or metastatic cancer. Dose-limiting toxicity (DLT) is defined as an adverse event (AE) during Cycle 1 (28 days) that was possibly related to the study drug and met 1 of the following criteria: According to the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0: ≥Grade 3 non-hematological toxicity except nausea/vomiting, diarrhea, or constipation that can be controlled with appropriate care; Grade 3 elevations of ALT and/or AST lasting fewer than 8 days (without evidence of other hepatic injury); Grade 3 rash that resolves or improves to a Grade 2 or less within 7 days; CTCAE Grade 4 hematological toxicity of \\>5 days duration; Grade 4 thrombocytopenia of any duration; Grade 3 thrombocytopenia with bleeding; Grade 3 febrile neutropenia.","groups":[{"description":"Cohort 1: 50 mg LY3009210 every 12 hours (hr) in a 28-day cycle.\n\nCohort 2 100 mg LY3009210 every 12 hr in a 28-day cycle.\n\nCohort 3: 200 mg LY3009120 every 12 hr in a 28-day cycle.\n\nCohort 4: 400 mg LY3009120 every 12 hr in a 28-day cycle.\n\nCohort 5: 500 mg LY3009120 every 12 hr in a 28-day cycle.\n\nCohort 6: 300 mg LY3009120 every 12 hr in a 28-day cycle.","id":"OG000","title":"Part A LY3009120"}],"paramType":"NUMBER","populationDescription":"All participants in Part A who received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"Cycle 1 (28 Days)","title":"Maximum Tolerated Dose (MTD) of LY3009120","type":"PRIMARY","unitOfMeasure":"milligrams (mg)"}